Major changes in the sphingophospholipidome of HDL in non-diabetic patients with metabolic syndrome

Atherosclerosis

Volumn 246, Issue , 2016, Pages 106-114

  Denimal, Damien ^a,b   Nguyen, Amandine ^b   Pais de Barros, Jean Paul ^a   Bouillet, Benjamin ^a,b   Petit, Jean Michel ^a,b   Vergès, Bruno ^a,b   Duvillard, Laurence ^a,b  

^a UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

HDL; Lipidomic; Metabolic syndrome; Phospholipids; Sphingolipids; Tandem mass spectrometry

Indexed keywords

FATTY ACID; GLYCEROPHOSPHOLIPID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; PLASMALOGEN; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOPHOSPHOLIPIDOME; SPHINGOSINE 1 PHOSPHATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHEMICAL COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIQUID CHROMATOGRAPHY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; BLOOD; CASE CONTROL STUDY; COMPLICATION;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PHOSPHOLIPIDS; SPHINGOLIPIDS; TANDEM MASS SPECTROMETRY;

EID: 84953304101     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.12.042     Document Type: Article

References (48)

1. Pischon T., Boeing H., Hoffmann K., Bergmann M., Schulze M.B., Overvad K., et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 2008, 359:2105-2120.
2. Moe B., Mork P.J., Holtermann A., Nilsen T.I. Occupational physical activity, metabolic syndrome and risk of death from all causes and cardiovascular disease in the HUNT 2 cohort study. Occup. Environ. Med. 2013, 70:86-90.
3. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
5. Kontush A., de Faria E.C., Chantepie S., Chapman M.J. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 2005, 182:277-285.
6. Hansel B., Giral P., Nobecourt E., Chantepie S., Bruckert E., Chapman M.J., et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 2004, 89:4963-4971.
7. Perségol L., Vergès B., Gambert P., Duvillard L. Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J. Lipid Res. 2007, 48:1396-1401.
8. Magkos F., Mohammed B.S., Mittendorfer B. Plasma lipid transfer enzymes in non-diabetic lean and obese men and women. Lipids 2009, 44:459-464.
9. Ebenbichler C.F., Laimer M., Kaser S., Ritsch A., Sandhofer A., Weiss H., et al. Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1465-1469.
10. Arai T., Yamashita S., Hirano K., Sakai N., Kotani K., Fujioka S., et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler. Thromb. 1994, 14:1129-1136.
11. Kontush A., Therond P., Zerrad A., Couturier M., Négre-Salvayre A., de Souza J.A., et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1843-1849.
12. Kontush A., Lhomme M., Chapman M.J. Unraveling the complexities of the HDL lipidome. J. Lipid Res. 2013, 54:2950-2963.
13. Camont L., Lhomme M., Rached F., Le Goff W., Nègre-Salvayre A., Salvayre R., et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2715-2723.
14. Argraves K.M., Sethi A.A., Gazzolo P.J., Wilkerson B.A., Remaley A.T., Tybjaerg-Hansen A., et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011, 10:70.
15. Sattler K., Lehmann I., Gräler M., Bröcker-Preuss M., Erbel R., Heusch G., et al. HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis. Cell. Physiol. Biochem. 2014, 34:172-184.
16. Horter M.J., Sondermann S., Reinecke H., Bogdanski J., Woltering A., Kerber S., et al. Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta Physiol. Scand. 2002, 176:123-130.
17. Meikle P.J., Wong G., Barlow C.K., Weir J.M., Greeve M.A., MacIntosh G.L., et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One 2013, 8:e74341.
18. Pietiläinen K.H., Sysi-Aho M., Rissanen A., Seppänen-Laakso T., Yki-Järvinen H., Kaprio J., et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-a monozygotic twin study. PLoS One 2007, 14(2):e218.
19. Ståhlman M., Fagerberg B., Adiels M., Ekroos K., Chapman J.M., Kontush A., et al. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles. Biochim. Biophys. Acta 2013, 1831:1609-1617.
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
21. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 22:497-509.
22. Denimal D., Pais de Barros J.P., Petit J.M., Bouillet B., Vergès B., Duvillard L. Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration. Atherosclerosis 2015, 241:752-760.
23. Bielawski J., Pierce J.S., Snider J., Rembiesa B., Szulc Z.M., Bielawska A. Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods Mol. Biol. 2009, 579:443-467.
24. Nofer J.R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Investig. 2004, 113:569-581.
25. Kimura T., Tomura H., Mogi C., Kuwabara A., Damirin A., Ishizuka T., et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 2006, 281:37457-37467.
26. Argraves K.M., Gazzolo P.J., Groh E.M., Wilkerson B.A., Matsuura B.S., Twal W.O., et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem. 2008, 283:25074-25081.
27. Theilmeier G., Schmidt C., Herrmann J., Keul P., Schäfers M., Herrgott I., et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006, 114:1403-1409.
28. Yang P., Subbaiah P.V. Regulation of hepatic lipase activity by sphingomyelin in plasma lipoproteins. Biochim. Biophys. Acta 2015, 1851:1327-1336.
29. Pont F., Duvillard L., Florentin E., Gambert P., Vergès B. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int. J. Obes. Relat. Metab. Disord. 2002, 26:1151-1158.
30. Subbaiah P.V., Jiang X.C., Belikova N.A., Aizezi B., Huang Z.H., Reardon C.A. Regulation of plasma cholesterol esterification by sphingomyelin: effect of physiological variations of plasma sphingomyelin on lecithin-cholesterol acyltransferase activity. Biochim. Biophys. Acta 2012, 1821:908-913.
31. Dullaart R.P., Perton F., Sluiter W.J., de Vries R., van Tol A. Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J. Clin. Endocrinol. Metab. 2008, 93:4860-4866.
32. Magkos F., Mohammed B.S., Mittendorfer B. Plasma lipid transfer enzymes in non-diabetic lean and obese men and women. Lipids 2009, 44:459-464.
33. Gruppen E.G., Connelly M.A., Otvos J.D., Bakker S.J., Dullaart R.P. A novel protein glycan biomarker and LCAT activity in metabolic syndrome. Eur. J. Clin. Investig. 2015, 45:850-859.
34. Broniec A., Klosinski R., Pawlak A., Wrona-Krol M., Thompson D., Sarna T. Interactions of plasmalogens and their diacyl analogs with singlet oxygen in selected model systems. Free Radic. Biol. Med. 2011, 50:892-898.
35. Sutter I., Velagapudi S., Othman A., Riwanto M., Manz J., Rohrer L., et al. Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis 2015, 241:539-546.
36. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Investig. 2004, 114:1752-1761.
37. Keaney J.F., Larson M.G., Vasan R.S., Wilson P.W., Lipinska I., Corey D., et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 2003, 23:434-439.
38. Julve J., Pardina E., Pérez-Cuéllar M., Ferrer R., Rossell J., Baena-Fustegueras J.A., et al. Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. Atherosclerosis 2014, 234:200-205.
39. Rana J.S., Arsenault B.J., Després J.P., Côté M., Talmud P.J., Ninio E., et al. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. Eur. Heart J. 2011, 32:336-344.
40. Tzotzas T., Filippatos T.D., Triantos A., Bruckert E., Tselepis A.D., Kiortsis D.N. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr. Metab. Cardiovasc. Dis. 2008, 18:477-482.
41. Rached F., Santos R.D., Camont L., Miname M.H., Lhomme M., Dauteuille C., et al. Defective functionality of HDL particles in familial apolipoprotein A-I deficiency: relevance of alterations in HDL lipidome and proteome. J. Lipid Res. 2014, 55:2509-2520.
42. Rached F., Lhomme M., Camont L., Gomes F., Dauteuille C., Robillard P., et al. Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. Biochim. Biophys. Acta 2015, 1851:1254-1261.
43. Kowalski G.M., Carey A.L., Selathurai A., Kingwell B.A., Bruce C.R. Plasma sphingosine-1-phosphate is elevated in obesity. PLoS One 2013, 8:e72449.
44. Caspar-Bauguil S., Fioroni A., Galinier A., Allenbach S., Pujol M.C., Salvayre R., et al. Pro-inflammatory phospholipid arachidonic acid/eicosapentaenoic acid ratio of dysmetabolic severely obese women. Obes. Surg. 2012, 22:935-944.
45. Song J., Kwon N., Lee M.H., Ko Y.G., Lee J.H., Kim O.Y. Association of serum phospholipid PUFAs with cardiometabolic risk: beneficial effect of DHA on the suppression of vascular proliferation/inflammation. Clin. Biochem. 2014, 47:361-368.
46. Gregor M.F., Yang L., Fabbrini E., Mohammed B.S., Eagon J.C., Hotamisligil G.S., et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009, 58:693-700.
47. Kammoun H.L., Chabanon H., Hainault I., Luquet S., Magnan C., Koike T., et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J. Clin. Investig. 2009, 119:1201-1215.
48. Wang Y., Botolin D., Xu J., Christian B., Mitchell E., Jayaprakasam B., et al. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J. Lipid Res. 2006, 47:2028-2041.